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Background: Bone marrow stromal cells (BMSCs) are multipotent cells that support angiogenesis, wound healing,
and immunomodulation. In the hematopoietic niche, they nurture hematopoietic cells, leukemia, tumors and
metastasis. BMSCs secrete of a wide range of cytokines, growth factors and matrix proteins which contribute to the
pro-tumorigenic marrow microenvironment. The inflammatory cytokines IFN-γ and TNF-α change the BMSC
secretome and we hypothesized that factors produced by tumors or leukemia would also affect the BMSC
secretome and investigated the interaction of leukemia cells with BMSCs.
Methods: BMSCs from healthy subjects were co-cultured with three myeloid leukemia cell lines (TF-1, TF-1α and
K562) using a trans-well system. Following co-culture, the BMSCs and leukemia cells were analyzed by global gene
expression analysis and culture supernatants were analyzed for protein expression. As a control, CD34+ cells were
also cocultured with BMSCs.
Results: Co-culture induced leukemia cell gene expression changes in stem cell pluripotency, TGF-β signaling and
carcinoma signaling pathways. BMSCs co-cultured with leukemia cells up-regulated a number of proinflammatory
genes including IL-17 signaling-related genes and IL-8 and CCL2 levels were increased in co-culture supernatants. In
contrast, purine metabolism, mTOR signaling and EIF2 signaling pathways genes were up-regulated in BMSCs
co-cultured with CD34+ cells.
Conclusions: BMSCs react to the presence of leukemia cells undergoing changes in the cytokine and chemokine
secretion profiles. Thus, BMSCs and leukemia cells both contribute to the creation of a competitive niche more
favorable for leukemia stem cells.
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Acute myeloid leukemia (AML) is a clonal, malignant
disorder. Treatment of AML is often complicated by dis-
ease propagation and relapse due to a small subset of
cells called leukemia stem cells (LSC). LSC show a less
mature phenotype compared with leukemia cells and
they display a constitutive activation of factors such as
NF-κB, Akt, and Wnt/β-Catenin which are involved in
survival and self-renewal [1-3]. Leukemia stem cells are a
heterogeneous population, which were first found among
CD34+CD38- populations, but they are also present among* Correspondence: DStroncek@cc.nih.gov
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stated.CD34+CD38+ and CD34- cells [4]. Normal hematopoietic
stem cells and LSCs reveal a high degree of similarity and
although LSCs show increased expression of CD44, CD96,
CD47 and the loss of CD90 expression, no unique LSC
marker has yet been found [5-9].
In the hematopoietic niche, LSCs interact with bone
marrow stromal cells (BMSCs) to create a microenviron-
ment that is favorable for LSC survival [10,11]. The interac-
tions between leukemia cells and the niche encompass
membrane receptors and soluble factors. These factors in-
clude CXCR4/CXCL12 (SDF-1) signaling, which is involved
in the homing, survival, and proliferation of leukemia cells
in AML [12,13] and chronic myeloid leukemia (CML) [14].
It is also important to note that CD44 and VLA-4 receptors
expressed by leukemia cells play a role in their adhesion totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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anti-apoptotic effects that support leukemia cell survival
[15,16].
BMSCs, which are also known as mesenchymal stromal
cells or mesenchymal stem cells, are a multipotent popu-
lation that plays an active role in the hematopoietic niche.
They maintain hematopoietic stem cells (HSCs) dormant
within the niche and they play a role in the release of acti-
vated HSCs [17-24]. These cells secrete a wide range of
cytokines, growth factors and matrix proteins involved in
the hematopoiesis and hematopoietic stem cells mainten-
ance [25-30].
It has been shown that in chronic lymphocytic leukemia
(CLL), BMSCs through cysteine-cysteine metabolism pro-
vide leukemia cells with the antioxidant species (GSH)
and promote cell survival in oxidative stress conditions
[31,32]. In multiple myeloma, BMSCs up-regulate the se-
cretion of several factors (IL-6, IGF-1, VEGF, FGF, SDF-1
and TNFα) as a result of their direct interaction with mye-
loma cells through integrins and soluble factors produced
by myeloma cells. This interaction of myeloma cells and
BMSCs in turn promotes a pro-tumorigenic environment
in which the survival, growth and drug resistance of mul-
tiple myeloma cells is guaranteed [33-35].
To further understand the interaction between BMSCs
and leukemia stem cells in the bone marrow microenvir-
onment, we selected three myeloid leukemia cell lines
with different degrees of stemness and co-cultured them
with BMSCs from healthy donors. We found that BMSCs
responded to leukemia cells by up-regulating many pro-
inflammatory and IL17-signaling related genes.
Methods
Study design
BMSCs from healthy donors were co-cultured with three
different myeloid leukemia cell lines. AML cell lines TF-1
and TF-1α were selected because of their phenotype:
CD34+/CD38+ and CD34+/CD38-, respectively; the TF-1α
phenotype being less mature than the TF-1 phenotype.
We also selected K562, a CD34- chronic myeloid leukemia
cell line, as a third cell line of bone marrow origin. A 1-μm
Transwell system (BD Biosciences, San Jose’, CA USA) was
used to maintain the cultured BMSC and leukemia cell
populations separate from each other. BMSCs were also
co-cultured under the same conditions with CD34+ cells
isolated from G-CSF-mobilized peripheral blood stem
cells from healthy donors BMSCs, leukemia and CD34+
cells cultured alone (mono-cultures) were used as con-
trols. Cells from both mono- and co-culture conditions
were harvested at 4 h, 10 h, and 24 h. Supernatants were
harvested at 48 h. Cells were analyzed for global gene
expression profiles, culture media for selected cytokines
and chemokines. These studies were approved by a NIH
Institution Review Board.Bone marrow stromal cells, leukemia cell lines and
hematopoietic stem cells
Passage 2 BMSCs from 4 healthy donor bone marrow
aspirates were provided by the Bone Marrow Stromal
Cell Transplant Center, NIH, Bethesda, Maryland. BMSCs
were expanded and characterized as described in our previ-
ous work [29,36]. Briefly, cells from bone marrow aspirates
were seeded in complete media (α −minimal essential
medium (α-MEM), 2 mM glutamine, 10 μg/ml gentamicin
and 20% fetal bovine serum) for 24 h, and the non-
adherent cells were removed. The adherent cells were ex-
panded until a 70-80% confluence was reached. Cells were
sub-cultured until passage 4 and kept in complete media.
Leukemia cell lines were purchased from ATCC: TF-1
(#CRL2003) CD34+/CD38+, TF-1α (ATCC #CRL2451)
CD34+/CD38- and K562 (ATCC #CCL243) CD34-. The
TF-1α and K562 cells were maintained in RPMI with 10%
FBS. TF-1 cells were kept in RPMI with 10% FBS and
2 ng/μl of GM-CSF until use in co-culture experiments.
Human CD34+ hematopoietic stem cells from three
different healthy donors were kindly provided by Dr J.
Miller (NIH-NIDDK). Peripheral blood stem cells (PBSC)
were collected by apheresis after 5 days of stimulation with
G-CSF and CD34+ cells isolated from the PBSCs using
CD34 antibodies conjugated to paramagnetic beads (Clin-
icMACS, Miltenyi Biotec Inc, Auburn, CA USA).
Co-culture
Passage 4 BMSCs were seeded in the 6-well plates at a
concentration of 5×104 cells/well, in RPMI plus 10% FBS
on day −1. At day 0, 1×106 TF-1, TF-1α, K562 and CD34+
cells were seeded into the Transwell system. Mono-
cultures of BMSCs, leukemia and CD34+ cells were seeded
at the same above mentioned conditions as controls. Cells
were harvested after 4 h, 10 h and 24 h, treated with
700 μl QIAzol (Qiagen, Valencia, CA USA) and were
stored at −80°C until use. Supernatants collected after
48 h were stored immediately at −80°C. For some studies
1×106 of the TF-1, TF-1α or K562 cells were cultured in
direct contact with passage 4 BMSCs in 6 well plates.
Total RNA purification, amplification, hybridization and
slide processing
Total RNA from co-culture and control samples was
purified using miRNA Easy Kit (Qiagen). The RNA con-
centration was measured using a Nano Drop ND-1000
Spectrophotometer (Nano Drop Technologies, Wilming-
ton, DE, USA) and RNA quality was assessed with an
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA).
RNA was amplified using an Agilent LowInput Quick-
Amp Labeling Kit Two color and subsequently co-hy
bridized with Universal Human Reference RNA (Strata-
gene, Santa Clara, CA, USA) on Agilent Chip Whole
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Statistical and microarray data analysis
Images of the arrays were acquired using a microarray
scanner Scan G2505B and image analysis was performed
using Scan Control software version 9.5 (Agilent Tech-
nologies). The images were extracted using the Feature
Extraction Software (Agilent Technologies). Partek Gen-
omic Suite 6.4 (Partek Inc., St. Louis, MO, USA) was
used for data analysis, visualization, identification of dif-
ferentially expressed transcripts (unadjusted p-value <
0.05) and hierarchical cluster analysis. Ingenuity Pathway
Analysis website (http://www.ingenuity.com, Ingenuity
System Inc., Redwood City, CA, USA) was used for ana-
lysis of functional pathways. The microarray data used
in this study have been deposited in National Center for
Biotechnology Information Gene Expression Omnibus
database (GSE45663).
Quantitative real-time PCR analysis
To validate the results of the microarray analysis, we per-
formed quantitative real-time PCR (RT-PCR) analysis on
total RNA from co-cultures and controls using 18S rRNA
as a housekeeping gene (Assay ID Hs99999901_s1, Applied
Biosystem-Life Technologies). Genes used for validation
were selected from those most up-regulated in co-cultured
cells compared to mono-culture controls: IL8, CCL2, ICA
M1 and IL1B. Gene expression data were quantified with
TaqMan Gene Expression Assay for each of the above
mentioned genes (Assay IDs: Hs99999034_m1, Hs00234
140_m1, Hs00164932_m1, Hs01555410_m1, respectively,
Life Technologies), according to manufacturer’s protocol.
For each sample, relative gene expression level was nor-
malized to 18S rRNA and determined by the 2-ΔΔCt
method. The reaction was performed using ABI Prism (BD
Biosystem, Life Technologies). The resulting data were an-
alyzed by SDS and RQ software (Applied Biosystem). The
results were shown as the relative co-culture mRNA level
to mono-culture control mRNA for the selected genes.
Proteome profiles (Human Cytokine Array Panel A array kit)
Supernatants collected from co-cultured and control cells,
after 48 h of culture, were thawed and immediately ana-
lyzed using the Human Cytokine Array Panel A array Kit
(R&D System, Inc., Minneapolis, MN USA) following the
manufacturer’s protocol. Briefly, 1 ml of supernatant was
incubated for 1 h with 15 μl of human cytokine detection
antibody cocktail. The suspension was incubated with the
provided membrane at 4°C for 30 h and treated with the
secondary antibody (Streptavidin-HRP) for 1 h at room
temperature. The membrane was exposed to chemilumin-
escence reagents SuperSignal West Pico Chemilumines-
cent Substrate (Thermo Scientific, Rockford, IL, USA).After exposing the membranes for 30 min to X-ray film,
the resulting film was scanned and the pixels were
counted and analyzed with ImageJ software (CIT, NIH
USA). The mean pixel density for each spot was calculated
by background subtraction and each value was normalized
by internal positive controls. Each sample was tested in
duplicate.
ELISA analysis
Levels of IL-8, and CCL2 in the supernatants from mono
and co-cultured samples were measured with enzyme-
linked immune adsorbent assays (Quantikine human kits;
R&D System) following the manufacturer’s instructions
using Victor3V ELISA reader (Perkin Elmer, Waltham, MA,
USA). Minimal detectable levels were: IL-8, 3.5 pg/ml and
CCL2, 1.7 pg/ml.
Results
Global gene expression analysis of BMSCs co-cultured
with leukemia cells reveals up-regulation of IL-17
signaling-related genes
To study the effects of leukemia cells on BMSCs, we co-
cultured BMSCs from healthy donors with three differ-
ent leukemia cell lines, TF-1α, TF-1 and K562, that were
selected according to their phenotypes: CD34+/CD38-,
CD34+/CD38+ and CD34-, respectively. The BMSCs and
leukemia cells were co-cultured in transwells without
physic contact. The cells were harvested at 4 h, 10 h and
24 h and total RNA was extracted. The gene expression
profiles of BMSC mono-cultures and BMSCs co-cultured
with the three leukemia cell lines were analyzed.
The overall comparison between mono- and co-culture
BMSCs revealed that 1540 BMSC genes were differentially
expressed (p-value <0.05). Supervised hierarchical cluster-
ing analysis of those genes clearly separated the BMSC
samples into two groups: co-cultured and mono-cultured
BMSCs (Figure 1A). We found that IL8, CXCL1, IL1B,
CXCL3, CCL2, CXCL3, CXCL2 and ICAM1 genes, all of
which are known to be involved in the acute inflammatory
response, were the most up-regulated genes in BMSCs co-
cultured with leukemia cells (Table 1). Ingenuity Pathway
Analysis (IPA) of the differentially expressed genes re-
vealed that the most over-represented canonical pathways
were the IL-17 signaling, CD40 signaling and NFκB signal-
ing pathways (Figure 1B). We also compared the micro-
array data from the different time points and we found
that most of the changes in the BMSC gene expression
profiles occurred within 4 h (data not shown).
Next, we checked if BMSCs responded differently to
the three different leukemia cell lines. The microarray
data were analyzed separately for BMSCs co-cultured
with the three different leukemia cell lines and we found
that BMSCs reacted somewhat differently when co-
cultured with each of the three leukemia cell lines. Using
BA
Figure 1 Gene expression analysis of BMSCs co-cultured with leukemia cells compared with BMSC mono-cultures shows changes in
IL-17 signaling-related genes. (A) Hierarchical clustering analysis of 1540 differentially expressed genes in BMSCs co-cultured in transwells with
three leukemia cell lines (TF-1, TF-1α and K562) compared with BMSC mono-cultures (control) using Partek Genomic Suite program (ANOVA test
with unadjusted p-value < 0.05). The displayed colors represent the fold changes where shades of red and blue indicate up- and down-regulation
respectively. The color key for the sample labels is on the top left. (B) Ingenuity Pathway Analysis (IPA) of the 1540 differentially expressed BMSC
genes. Numerical symbols at the right side of each bar indicate the total number of genes composing the pathway. The bars indicate the
percentage of up- (red bar) and down-regulated (green bar) genes in each pathway, while the orange line indicates minus-log transformed
p-value. The top 10 canonical pathways are shown.
Table 1 Change in expression of BMSC genes during
co-culture with leukemia cells
Up-regulated genesa Down-regulated genesa
Gene symbol Fold change Genes symbol Fold change
IL8 19.9 ANGPT2 −3.4
CXCL1 19.7 CSRNP3 −2.8
IL1B 8.8 TMEM26 −2.7
CXCL3 7.6 GPR85 −2.6
CCL2 7.3 F2RL2 −2.6
CXCL2 6.3 FOSB −2.5
ICAM1 5.2 PROCK3 −2.4
SERPINB2 4.6 AP4E1 −2.4
PTGS2 4.5 EVC −2.3
aComparison of co-cultured and mono-cultured BMSCs (p-value < 0.05).
The genes with the greatest fold change are shown.
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entially expressed genes in BMSCs co-cultured with TF-1,
TF-1α and K562 compared with BMSC mono-cultures
were 1775, 1375 and 1738 respectively. The genes IL8,
CCL2, CXCL1, IL1B and ICAM1 were among the most up-
regulated genes in BMSCs co-cultured with both TF-1 and
K562 although with significantly different fold changes
(Table 2). In contrast, analysis of BMSCs co-cultured with
TF-1α revealed a different signature with a mild up-
regulation of IRF8 and CADHERIN7 and a down-regulation
of COL3A1 (Table 2). Ingenuity pathway analysis of the three
separate sets of BMSC differentially expressed genes revealed
that the top canonical pathways involved were IL-17 signal-
ing, CD40 signaling and IL-6 signaling in BMSCs co-
cultured with TF-1 and K562, while Rac signaling, actin
cytoskeleton signaling, growth hormone signaling and death
Table 2 Change in expression of BMSC genes during co-culture with 3 different leukemia cell lines and with CD34+ cells
Class comparisona Up-regulated genes Down-regulated genes Most over-represented canonical pathwaysb
Gene symbol Fold change Genes symbol Fold change
BMSCs co-cultured with TF-1
CXCL1 338.3 CYP3A4 −5.9 Role of IL-17A in arthritis
IL8 168.8 PLEKHH2 −4.2 Role of IL-17 F in allergic Inflammatory
airway Diseases
CXCL3 59.4 CCNF −4.0 Role of IL-17A in Psioriasis
CXCL2 46.6 CYP3A5 −3.9 IL-17A signaling in airway cells
PTGS2 32.8 RBM5 −3.8
IL1B 26.6 BMP4 −3.8
IL1A 26.5 ANGPT2 −3.7
IL1B 23.1 GZMB −3.5
ICAM1 21.7 DAB2IP −3.5
CCL2 19.3 CYP3A7 −3.5
BMSCs co-cultured with TF-1α
IRF8 4.2 Col3a1 −14.4 Rac signaling
SLC30A4 4.0 Gria1 −6.6 D-myo-inositol(1,4,5) triphosphate biosynthesis
CDH7 3.2 ASB5 −5.5
DZANK1 3.0 ABCC9 −5.2 Actin cytoskeleton signaling
GDF2 3.0 DBIL5P −4.2 Growth hormone signaling
NPTX1 2.9 CALB2 −3.5 Death receptor signaling
ATPBD4 2.9 TMEM242 −3.5
UNC5C 2.9 EIF4EBP2 −3.4
YOD1 2.9 −3.1
CCL28 2.8 MLL2 −3.0
BMSCs co-cultured with K562
IL8 17.4 SPOCK3 −7.1 Role of IL-17A in arthritis
CCL2 12.6 KANK4 −6.5 Hepatic fibrosis/stellate cell activation
PTPRR 11.9 PRSS35 −6.5 VDR/RXR activation
IL1B 11.6 GPR85 −5.5 CD40 signaling
CXCL1 9.2 FGF7 −4.7 IL-6 signaling
ICAM1 8.4 SLC8A1 −4.6
SLC25A21 7.6 AP4E1 −4.6
SERPINB2 7.5 ABCC9 −4.2
SLC44A4 6.1 C17orf28 −4.2
FAM167A 5.0 FLT1 −4.1
BMSCs co-cultured with
CD34+ cells
SERPINB2 3.5 UGT2B10 −2.9 Purine metabolism
IL1B 3.4 METTL3 −2.7 Estrogen receptor signaling
RTP3 2.8 SFP2 −2.6 mTOR signaling
ZBED2 2.7 C5AR1 −2.5 EIF2 signaling
CCL7 2.6 ISL2 −2.5 Aminosugars metabolism
ERMN 2.6 KLRC3 −2.4
IL8 2.6 EFHD1 −2.3
NKAPL 2.5 RFX4 −2.3
TSLP 2.4 KANK4 −2.2
aComparison of co-cultured and mono-cultured BMSCs (p-value <0.05).
bIngenuity pathway analysis (IPA).
The genes with the greatest fold change are shown.
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canonical pathways in BMSC co-cultured with TF-1α
(Table 2).
To validate the microarray data, we performed quanti-
tative RT-PCR analysis. The RT-PCR results confirmed
the greater expression of CCL2, ICAM1, IL8 and IL1B in
BMSCs co-cultured with leukemia cells compared with
BMSC mono-cultures (Figure 2).
To study the effects of BMSCs on leukemia cells, the
gene expression profiles of TF-1, TF-1α and K562 leu-
kemia cells alone and co-cultured with BMSCs were ana-
lyzed by microarrays. The microarray data were analyzed
using Partek Genomic Suite and the analysis revealed that
1138, 1119 and 943 genes were differentially expressed
(p-value <0.05) in TF-1, TF-1α and K562 cells co-cultured
with BMSCs compared with the respective leukemia cell
mono-cultures. Among the most up-regulated genes were
RGS1, FAM69A, Skg1 and SOCSs, although their fold
change in expression was <7. Ingenuity pathway analysis
(IPA) of the differentially expressed genes revealed thatFigure 2 The expression of IL-17 signaling-related genes increase in B
performed to quantify the expression levels of CCL2, ICAM1, IL8 and IL1B in
and K562(3) leukemia cell (LC) (white bars) mono-cultures, BMSCs co-cultur
column) and BMSCs co-cultured in transwells with CD34+ cells (grey and b
Sample key legend is at the top right. * p-value < 0.05the most represented canonical pathways were stem cells
pluripotency, TGF-β signaling and carcinoma signaling
(Table 3).
Next, we studied the effects of leukemia cells on
BMSCs co-cultured in direct contact. BMSCs from three
healthy donors were co-cultured with the three different
leukemia cell lines in direct contact. The cells were har-
vested at 4 h, 10 h and 24 h and total RNA was ex-
tracted. The total RNA from BMSC mono-cultures was
mixed with the total RNA from TF-1, TF-1α or K562 cell
mono-cultures and the resulting three mixed total RNA
samples were used as a “mono-culture” control in the gene
expression profiling analysis. The RNA from BMSCs co-
cultured with the TF-1, TF-1a and K562 cells were ex-
tracted and the gene expression profiles were analyzed by
microarrays. The analysis of microarray data using Partek
Genomic Suite revealed that 544 genes were differentially
expressed between co-cultured and mono-cultured control
cells (p-value <0.05, FDR <0.01). Hierarchical clustering
analysis of these genes clearly separated the samples intoMSCs co-cultured with leukemia cells. Quantitative RT-PCR was
BMSCs (black column), CD34+ cells (grey bars) and TF-1 (1), TF-1a(2)
ed in transwells with leukemia cell lines (black and white stripped
lack stripped column). The RNA levels were shown as 2-ΔΔCt method.
Table 3 Change in expression of leukemia and CD34+ cell genes during co-cultured with BMSCs
Class comparison1 Up-regulated genes Down-regulated genes Most over-represented canonical pathways2
Gene symbol Fold change Genes symbol Fold change
TF-1 cells co-cultured with BMSCs RGS1 6.04 HARS2 −4.44 Role of NANOG in stem cells pluripotency
TST 4.93 CBL −4.14 CNTF signaling
CD93 4.46 WDR31 −3.56 Growth hormone signaling
AZGP1 4.34 PIGR −3.37 IGF-1 signaling
CD200R1 3.95 SLC12A1 −3.19 Stem cells pluripotency
CTNND! 3.37 CTTNBP2 −3.11
ASAP2 3.28 C6orf105 −2.97
CLEC4M 3.23 ATP2B4 −2.79
CACNA1F 3.20 SLC16A6 −2.75
SOCS7 3.19 SLC38A10 −2.74
TF-1α cells co-cultured with BMSCs FAM69A 4.22 ADPRH −7.62 Role of macrophages in rheumatoid arthritis
LIM2 3.96 SIGLEC12 −6.85 Axonal guidance signaling
KCNMB2 3.60 XIRP2 −5.00 Basal cell carcinoma signaling
C1QL1 3.28 KRT2 −4.42 G-protein coupled receptor signaling
TULP1 3.27 GPR180 −3.91 ERK/MAPK signaling
DIS3 3.22 KLHL1 −3.87
IGFBP4 3.22 GALNT4 −3.55
SSPN 3.19 PDGFC −3.50
ATP11A 3.18 PFN4 −3.32
SLC25A2 3.07 GPR37L1 −3.27
K562 cells co-cultured with BMSCs SKG1 3.66 EPB42 −5.78 Role of Oct4 in stem cell pluripotency
KLARN 3.41 EPX −5.00 Antigen presentation pathway
CNN1 3.31 BPIFA1 −4.38 TGF-β signaling
AFF3 3.11 LEPR −3.93 Regulation of IL-2 expression in T lymphocyte
SKIL 3.04 ANKRD11 −3.24 Semaphorin signaling in neurons
SLC2A12 2.93 HIST1H1B −3.18
ATXN7 2.80 SORBS1 −3.15
LEFTY1 2.52 CYP4A11 −3.10
DMBT1 2.41 GRWD1 −3.07
CELF2 2.34 CNOT4 −2.91
CD34+ cells co-cultured with BMSCs SOCS3 14.45 HMOX1 −3.26 cAMP-mediated signaling
REN 11.56 C18orf1 −3.17 VDR/RXR activation
ECEL1 7.70 POU2F2 −3.09 Cardiac β-adrenergic signaling
ATP6V0A4 7.63 PLD4 −3.07 Dopamine-DARPP32 feedback in
cAMP signaling
NR4A3 6.83 GPR44 −3.06
GEM 6.79 RXFP1 −2.93
HAS1 6.64 TNFSF14 −2.92
KIAA1199 6.48 ENC1 −2.78
PDLIM3 6.22 CST6 −2.68
CXCL6 5.74 CYTH4 −2.62
1Comparison of leukemia or CD34+ cells co-cultured with BMSCs compared with mono-cultured leukemia or CD34+ cells (p-value < 0.05, FDR < 0.01).
2Ingenuity Pathway Analysis (IPA).
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Figure 3 Gene expression analysis of BMSCs co-cultured in direct contact with leukemia cells shows changes in IL-17 signaling-related
genes. BMSCs from three healthy donors were co-cultured in direct contact with the three different leukemia cell lines (TF-1, TF-1α and K562).
The cells were harvested at 4 h, 10 h and 24 h and total RNA were extracted. The total RNA from BMSC mono-cultures was mixed with the total
RNA from TF-1, TF-1α or K562 cell mono-cultures and the resulting three mixed total RNA samples were used as a “mono-culture” control and
were subjected to gene expression analysis. The RNA from BMSCs and leukemia cells co-cultured in direct contact was extracted and gene
expression was analyzed. Analysis with Partek Genomic Suite revealed that 544 genes that were differently expressed between the BMSCs and
leukemia cell direct contact co-culture samples and the mono-culture controls (p-value < 0.05, FDR < 0.01). Panel A; Hierarchical clustering analysis of
544 differentially expressed genes in BMSCs and leukemia cell direct contact co-cultre samples compared with the mono-cultures (control) using Partek
Genomic Suite program (ANOVA test with unadjusted p-value < 0.05). The displayed colors represent the fold changes where shades of red and blue
indicate up- and down-regulation respectively. The color key for the sample labels is on the top left. Panel B. Ingenuity Pathway Analysis (IPA) of the
544 differentially expressed genes. Numerical symbols at the right side of each bar indicate the total number of genes composing the pathway. The
bars indicate the percentage of up- (red bar) and down-regulated (green bar) genes in each pathway, while the orange line indicates minus-log
transformed p-value. The top 10 canonical pathways are shown.
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The results were similar to the analysis of BMSCs co-
cultured in transwells with the leukemia cells. We found
that CXCL1, CXCL6, TEP1, IL8, CCL2 and PTGS2 genes
were the most up-regulated genes in BMSCs co-cultured
in the direct contact with leukemia cells. Ingenuity Path-
way Analysis of the differentially expressed genes revealed
that the top canonical pathways involved were the gluco-
corticoid receptor signaling, IL-17 signaling and acute
phase response signaling (Figure 3B).
Gene expression analysis of BMSCs co-cultured with CD34+
cells revealed changes in metabolism related genes
To evaluate whether the observed BMSC gene induction
was specifically induced by leukemia cells, BMSCs were
co-cultured in transwells with CD34+ cells from healthydonors. The BMSCs were harvested at 4 h, 10 h and
24 h and total RNA was extracted. The gene expres-
sion profiles of BMSC mono-cultures and co-cultured
with the CD34+ cells were analyzed by microarrays.
Analysis of the microarray data revealed that 4904
genes were differentially expressed between the two
groups (p-value <0.05). Hierarchical clustering analysis
of those genes separated the BMSCs into two groups
but the separation between co-cultured and mono-
cultured cells was not perfect. One group consisted of
8 co-cultured samples and 2 mono-cultures; the sec-
ond group consisted of 7 mono-cultured samples and
1 co-cultured sample (Figure 4A). We found that the
most up-regulated genes in BMSCs co-cultured with
CD34+ cells compared with BMSC mono-cultures
were SERPINB2, IL1B, RTP3, CCL7 and IL8 (Table 2).
A B
Figure 4 Gene expression analysis of BMSCs co-cultured with CD34+ cells compared with BMSC mono-cultures shows changes in
metabolism related genes. (A) Hierarchical cluster analysis of 4904 differentially expressed genes in BMSCs co-cultured in transwells with CD34+
cells from three healthy donors compared with BMSC mono-cultures (control) using Partek Genomic Suite program (ANOVA test with unadjusted
p-value < 0.05). The displayed colors represent the fold changes with the shades of red and blue indicating up- and down-regulation respectively.
The color key for the sample labels is on the top left. (B) Ingenuity Pathway Analysis (IPA) of the 4904 differentially expressed BMSC genes.
Numerical symbols at the right side of each bar indicate the total number of genes in each pathway. The bars indicate the percentage of
up- (red bar) and down-regulated (green bar) genes in each pathway, while the orange line indicates minus-log transformed p-value. The top 10
canonical pathways are shown.
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http://www.translational-medicine.com/content/11/1/298Ingenuity pathway analysis (IPA) revealed that the top ca-
nonical pathways involved were the purine metabolism,
mTOR signaling and EIF2 signaling (Figure 4B). To valid-
ate the microarrays data, we performed a quantitative RT-
PCR analysis which confirmed the greater expression of
IL8 in BMSCs co-cultured with CD34+ cells compared
with BMSC mono-cultures (Figure 2).
Similarly to what was done with the leukemia cell lines,
to study the effects of BMSCs on CD34+ cells, gene ex-
pression profiles from CD34+ cell mono-cultures and co-
cultures with BMSCs were analyzed by microarrays. We
found that 2075 genes were differentially expressed
(p-value <0.05) in CD34+ cell co-cultures compared with
mono-cultures. Among the most up-regulated genes were
SOCS3, REN and CXCL6; all with a fold change >5. Ingenu-
ity pathway analysis of the differentially expressed genes re-
vealed that the most represented canonical pathways werecAMP-mediated signaling, VDR/RXR activation and car-
diac β-adrenergic signaling (Table 3).
CCL2 and IL-8 are increased in supernatants from BMSCs
co-cultured with leukemia cells
Gene expression analysis revealed that most of the genes
up-regulated in BMSCs co-cultured with leukemia cells
were involved in IL-17 signaling. To assess the factors
produced by co-cultured cells, we screened the superna-
tants from co-culture and mono-culture samples at 48 h
for cytokine production by R&D Human Cytokine panel
A. We chose this panel because among the 36 cytokines
in the panel were CXCL1, sICAM-1, IL-1B, IL-8, CCL2
and Serpin E1 all of which were found to be up-regulated
at the gene level in co-cultured BMSCs. Moreover, with
panel A we were able to measure the relative levels of
IFNγ, IL-6 and IL-23 which are IL-17 signaling-related
Civini et al. Journal of Translational Medicine 2013, 11:298 Page 10 of 14
http://www.translational-medicine.com/content/11/1/298cytokines. However, most of the 36 cytokines in the panel
were undetectable in our samples and the levels of cyto-
kines CXCL1, ICAM-1, IL-23, IL-6, MIF and Serpin E1
were not significantly changed between co-culture and
mono-culture conditions (data not shown). However, the
levels of CCL2 and IL-8 were greater in supernatants from
BMSCs co-cultured with leukemia cells (Figure 5), but the
results were variable among BMSCs from different subjects.
The levels of IFNγ and CD40L were greater in co-culture
compared with mono-culture supernatants, but the differ-
ence was not statistically significant. The analysis of cyto-
kines in the supernatant of cultured BMSCs and leukemia
cells was performed in three series of experiments with
BMSCs from three healthy donors, (BMSC002, BMSC003
and BMSC006) and we found different responses among
the different BMSC donors. We found increased levels ofIL-8
Figure 5 IL-17 signaling-related cytokine levels are greater in superna
from the cultures were harvested after 48 hours and tested for soluble fact
mono-cultures (black bars), TF1, TF-1α and K562 leukemia cell mono-cultures
transwells with leukemia cells (black and white stripped bars) and BMSCs co-c
expression of selected cytokines was measured using array protein panel A (R
were calculated as a mean pixel density after normalization with positive con
top right. The histograms represent results of 3 experiments with BMSCs fromIFNγ and CD40L only in the supernatants from BMSC003
co-cultured with TF-1 and TF1α. The levels of IL-8 were
increased in the supernatants from BMSC003, BMSC006
and, to a lesser extent, in BMSC002. The level of CCL2
was measurable only in supernatants from BMSC003,
BMSC002 and BMSC006 co-cultured with TF-1 and K562
leukemia cells and in the supernatant from BMSC006 co-
cultured with TF-1α (Figure 6).
To confirm the increased levels of CCL2 and IL-8 in the
supernatants from BMSCs co-cultured with leukemia cells
at 48 h, we measured the levels of the two cytokines using
ELISA assays. We co-cultured BMSCs from 3 different
healthy donors with TF-1, TF-1α and K562 leukemia cells
and harvested the supernatants from the co-cultures and
mono-cultures at 48 h. We found that the concentration
of CCL2 in BMSCs and TF-1, TF-1α and K562 mono-tants from BMSCs co-cultured with leukemia cells. Supernatants
ors using an immunoblotting assay. The supernatants were from BMSC
(white bars), CD34+ cells mono-cultures (grey bars), BMSCs co-cultured in
ultured with CD34+ cells (black and grey stripped bars). The relative
&D System). The relative concentrations of IFN-γ, CD40L, CCL2 and IL-8
trol and background subtraction. The sample labeling legend is at the
three different healthy donors.
Figure 6 IL-17 signaling-related cytokine levels increase in supernatants from BMSCs co-cultured with leukemia cells: comparison of
the effects of BMSCs from 3 different donors. BMSC mono-culture (black bars), TF1 (1), TF-1a (2) and K562 (3) leukemia cell (LC) mono-culture
(white bars) and CD34+ cell mono-culture (grey bars), BMSC/leukemia cell transwell co-culture (black and white stripped bars) and BMSC/CD34+
cell transwell co-culture (black and grey stripped bars) supernatants were harvested after 48 h. The relative expression of selected cytokines was
measured using array protein panel A (R&D System) immunobloting assay. The relative amounts of IFN-γ, CD40L, CCL2 and IL-8 were calculated
as a mean pixel density after normalization with positive control and background subtraction. The sample labeling legend is at the top right. The
results of 3 experiments with BMSCs from three healthy donors (BMSC006, BMSC002 and BMSC003) are shown.
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http://www.translational-medicine.com/content/11/1/298cultures was 310.9 ± 77.3 pg/ml, 108.3 ± 74 pg/ml, 262 ±
112 pg/ml and 63.6 ± 30.7 pg/ml respectively. The concen-
tration of CCL2 increased significantly in the supernatant
of BMSCs co-cultured with TF-1, TF-1α and K562 (2482 ±
647 pg/ml, 915.3 ± 103 pg/ml and 1434 ± 298 pg/ml re-
spectively) (Figure 7). The concentration of IL-8 in BMSC
monocultures was <3.5 pg/ml for two of the donors and
was 9.8 pg/ml in the third donor. The concentration of the
secreted IL-8 was <3.5 pg/ml in the supernatants from TF-
1 and K562 mono-cultures, but was higher (68.4 pg/ml) in
the supernatants from TF-1α mono-cultures. The concen-
tration of IL-8 increased in BMSCs co-cultured with TF-1,
TF-1α and K562 (4216 ± 2760 pg/ml, 194 ± 180 pg/ml and
326.2 ± 300 pg/ml respectively) (Figures 7 and 8).
Discussion
The purpose of our study was to investigate the effect of
the leukemia microenvironment on bone marrow stro-
mal cells. BMSCs support both normal and abnormal
hematopoiesis. In leukemia microenvironment they play
an important and complex role: BMSCs promote AML
cell growth and drug resistance [37] via IL-6 secretion,
JAK/STAT pathway activation [38] and by activating
pro-survival pathways via integrin-linked kinases [39]. Inchronic myeloid leukemia, BMSCs stabilize leukemia
cells by promoting the clustering of CXCR4 in the lipid
rafts and facilitating the migration of leukemia cells in
the bone marrow [14]. BMSCs via the secretion of sol-
uble factors also inhibit drug-induced apoptosis of AML
[40] and myeloma cells [41]. It has been found that con-
ditioned media from BMSCs cultured alone had no ef-
fect on myeloma cells, but soluble factors produced by
BMSCs in contact with myeloma induced some anti-
apoptotic properties suggesting a dynamic interaction
between BMSCs and myeloma [41].
Our studies found a similar dynamic relationship be-
tween BMSCs and leukemia cells. We confirmed that
BMSCs affect leukemia cells and found that leukemia
cells change the profile of cytokines produced by BMSCs
to a proinflammatory signature. These changes did not
require direct contact between BMSCs and leukemia cells;
they were mediated by soluble factors. In an in vitro co-
culture model, BMSCs responded to the presence of
leukemia cells undergoing changes in gene expression and
cytokine release. After co-culture with leukemia cells 1540
BMSC genes were differentially expressed. The most up-
regulated genes were involved in the acute inflammatory
















Figure 7 CCL2 and IL-8 supernatant levels are greater in BMSCs co-cultured with leukemia cells. BMSC mono-culture (black bars), TF1,
TF-1α and K562 leukemia cell mono-culture (white bars) and BMSC/leukemia cell transwell co-cultures (black and white stripped bars) supernatants
were harvested after 48 h. The concentration (pg/ml) of CCL2 and IL-8 was measured using an ELISA assay. The sample labeling legend is at the top
left. The figures represent the results of 3 experiments with BMSCs obtained from three different healthy donors.
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http://www.translational-medicine.com/content/11/1/298pathways. Moreover, in co-culture the levels of the IL-17
signaling pathway proteins CCL2 and IL-8 were increased
in the culture supernatants. The IL-17 signaling pathway is
highly involved in the inflammatory process, auto-immune
diseases and in the tumor microenvironment [42].
The leukemia cell-induced changes in BMSCs were
different than those induced by CD34+ cells. The CD34+
cells from healthy donors induced changes in 4904
BMSC genes, but the fold change in expression was low.
The genes most up-regulated by CD34+ cells were SER-
PINB2, IL1B, RTP3, CCL7 and IL8, and the pathwaysFigure 8 CCL2 and IL-8 levels increase in supernatants from BMSCs c
BMSCs from 3 different donors. BMSC mono-culture (black bars), TF-1 (1
BMSC/leukemia cell transwell co-culture (black and white stripped bars) sup
IL-8 was measured by an ELISA assay. The sample labeling legend is at the
donors (BMSC006, BMSC002 and BMSC003) are shown.most represented among the differentially expressed
genes were involved with metabolism.
Our gene expression profiling results found some
differences in the effects of the three leukemia cell
lines on BMSCs: TF-1 and K562 stimulated BMSC
pro-inflammatory molecule production, while TF-1α down-
regulated BMSC Col3A1 expression and up-regulating IRF8
although with a small fold change and the pathways most
represented in the differentially expressed genes included
Rac, actin cytoskeleton, growth factor hormone and death
receptor signaling.o-cultured with leukemia cells: comparison of the effects of
), TF-1a (2) and K562 (3) leukemia cell mono-culture (white bars) and
ernatants were harvested after 48 h. The amount (pg/ml) of CCL2 and
top left. The results of 3 experiments with BMSCs from three healthy
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http://www.translational-medicine.com/content/11/1/298The analysis of BMSC-leukemia cell co-culture super-
natant partially confirmed our gene expression data. The
factors CCL2, IL-8, IFN-γ and CD40L were detected in the
supernatant. We found that the level of CCL2 was the high-
est in BMSCs co-cultured with TF-1, lower with K562 and
the lowest in BMSCs co-cultured with TF-1α. The levels of
IFN-γ, CD40L and IL-8 were elevated in the co-culture
supernatants; however, the magnitude of the changes in the
factor levels differed among the three leukemia cell line
experiments confirming their different effects on BMSCs.
We selected the leukemia cell lines according to their
phenotype, with TF-1α being closer in phenotype to a
leukemia stem cell and our results suggest that BMSCs
might react to leukemia cells in a different way than
LSCs. The variance in the effects of 3 leukemia cell lines
also suggest that differences in the nature of the effects
of the leukemia cells on BMSCs might contribute to dif-
ferences in the clinical presentation among leukemia
types. Interestingly, previously published studies of pa-
tients with myeloid leukemia and acute lymphocytic
leukemia have shown a deregulation of serum cytokine
and chemokine profiles including higher levels of CCL2
and IL-8 [43-46] and in myeloid leukemia elevated levels
of CCL2 and IL-8 were associated with an unfavorable
prognosis [43-45]. Other studies have found that CCL2
and IL-8 inhibit myeloid progenitor proliferation [47-49].
We also noted differences in supernatant factor levels
among cultures with BMSCs from different donors. This is
likely due to differences among the BMSCs. Our group has
previously shown substantial variance among BMSCs from
healthy donors [50]. The results of the current study found
that the cytokine expression was variable among the assays
which used BMSCs from three different donors; BMSCs
from only one of the donors reacted to the leukemia cells
by increasing the expression of IFNγ and CD40L. More-
over, the levels of CCL2 and IL-8 increased in the BMSCs
from all three donors, but by different amounts. We spe-
culate that variances among patients in outcome and
response to the treatment might also be ascribable, in part,
to differences among their bone marrow stromal cells.
Others have also studied BMSC donor variations in cyto-
kines expression profile and have found that the basal and
post-inflammatory stimulation cytokine/chemokine pro-
files are donor-dependent in in vitro experiments [51].
Much of the change in BMSCs induced by leukemia cells
is likely due to soluble factors secreted by leukemia cells.
In conclusion, our results reveal that BMSCs react
to leukemia cells by changing the profile of their ex-
pressed cytokines and chemokines to an IL-17 signal-
ing profile. In a microenvironment as finely regulated
as the hematopoietic niche, this alteration of secreted
factors likely collaborates with leukemia features to
create a competitive niche more favorable to leukemia
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